TCGA-CF-A7I0-01A-22R-A352-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 12.08935611
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.310
- KRAS_SIGNALING_DN+0.270
- WNT_BETA_CATENIN_SIGNALING+0.250
- HEDGEHOG_SIGNALING+0.200
- PANCREAS_BETA_CELLS+0.200
- ANGIOGENESIS+0.190
- ESTROGEN_RESPONSE_EARLY+0.130
- KRAS_SIGNALING_UP+0.130
- ESTROGEN_RESPONSE_LATE+0.120
- BILE_ACID_METABOLISM+0.110
Top 10 suppressed
- E2F_TARGETS-0.590
- G2M_CHECKPOINT-0.590
- INTERFERON_ALPHA_RESPONSE-0.570
- PROTEIN_SECRETION-0.530
- MYC_TARGETS_V1-0.490
- MYC_TARGETS_V2-0.490
- UNFOLDED_PROTEIN_RESPONSE-0.490
- MITOTIC_SPINDLE-0.480
- MTORC1_SIGNALING-0.480
- INTERFERON_GAMMA_RESPONSE-0.470
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD001526_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.942 |
| 2 | TCGA-XF-A9SH-01A-11R-A39I-07 | — | — | 0.921 |
| 3 | SRR1500868 | GTEX | — | 0.912 |
| 4 | MNG768 | — | — | 0.910 |
| 5 | TCGA-W8-A86G-01A-21R-A36F-07 | — | A | 0.909 |
| 6 | BS_3T6X4BPC | DNET | — | 0.909 |
| 7 | TCGA-DK-A3IK-01A-32R-A21D-07 | — | — | 0.908 |
| 8 | SRR1477080 | GTEX | — | 0.907 |
| 9 | SRR1388378 | GTEX | — | 0.906 |
| 10 | SRR1331751 | GTEX | — | 0.904 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.310 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.270 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.250 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.190 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.130 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.130 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.120 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| COAGULATION | 0.110 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.070 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.070 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.050 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.030 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.010 | Idelalisib | — uncovered |